Intellia Therapeutics (NTLA) Receiving Favorable Press Coverage, Study Shows

News stories about Intellia Therapeutics (NASDAQ:NTLA) have been trending positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Intellia Therapeutics earned a news sentiment score of 0.25 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.758666238401 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Shares of Intellia Therapeutics (NASDAQ:NTLA) opened at $23.00 on Monday. Intellia Therapeutics has a 1-year low of $10.83 and a 1-year high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. The firm had revenue of $7.30 million during the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. Intellia Therapeutics’s revenue for the quarter was up 49.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.22) EPS. equities analysts expect that Intellia Therapeutics will post -1.68 EPS for the current fiscal year.

Several equities analysts have recently issued reports on NTLA shares. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Leerink Swann boosted their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Barclays reaffirmed a “buy” rating on shares of Intellia Therapeutics in a report on Sunday, November 5th. ValuEngine downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Finally, Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a research report on Tuesday, August 29th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $30.17.

TRADEMARK VIOLATION NOTICE: “Intellia Therapeutics (NTLA) Receiving Favorable Press Coverage, Study Shows” was published by Week Herald and is the property of of Week Herald. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://weekherald.com/2017/12/04/intellia-therapeutics-ntla-earns-daily-coverage-optimism-rating-of-0-25.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Insider Buying and Selling by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply